Using dodecameric SP-D, SP-D inhibitory receptors (2), virus removal by other pattern recognition proteins [SP-A, pentameric C-reactive protein, innate immunoglobulin M (IgM) natural antibodies, Toll-like receptor inhibitors, and others] will facilitate reduction of lung disease severity in particular (Figure 1), and COVID-19 disease in general. Here, SFTPD is linked to lung disorder.